Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 multicenter study in relapsed/refractory multiple myeloma (CRB-401) (n = 62; median follow-up, 18.1 months). The primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi, Raje, Noopur S., Berdeja, Jesús G., Siegel, David S., Jagannath, Sundar, Madduri, Deepu, Liedtke, Michaela, Rosenblatt, Jacalyn, Maus, Marcela V., Massaro, Monica, Petrocca, Fabio, Yeri, Ashish, Finney, Olivia, Caia, Andrea, Yang, Zhihong, Martin, Nathan, Campbell, Timothy B., Rytlewski, Julie, Fuller, Jaymes, Hege, Kristen, Munshi, Nikhil C., Kochenderfer, James N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504071/
https://www.ncbi.nlm.nih.gov/pubmed/37592106
http://dx.doi.org/10.1038/s41591-023-02496-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504071/
https://www.ncbi.nlm.nih.gov/pubmed/37592106
http://dx.doi.org/10.1038/s41591-023-02496-0

Ejemplares similares